TDP-43 was demonstrated to interact with NF-κB, and an NF-κB inhibitor reduced ALS disease symptoms in a TDP-43 transgenic mouse model (Swarup et al., 2011). Here, NFKB1 is linked to amyotrophic lateral sclerosis.